Prestige Consumer Healthcare (PBH) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xencor (XNCR) has outperformed Prestige Consumer Healthcare (PBH) over the past year, gaining 109.6% versus a loss of 16.5%. Over five years, XNCR leads with a -6.2% price change compared with -12.0% for PBH. Xencor is the larger company by market cap ($2.50 billion vs $2.35 billion), about 1.1 times the size.
Prestige Consumer Healthcare converts more of its revenue into profit, with a net margin of 17.5% versus -73.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBH | XNCR |
|---|---|---|
| Share price | $49.63 | $33.26 |
| Market cap | $2.35B | $2.50B |
| 1-day change | +0.06% | -2.21% |
| YTD return | -19.55% | +117.24% |
| 1-year return | -16.48% | +109.58% |
| 5-year return | -12.02% | -6.15% |
| P/E ratio (TTM) | 15.32 | — |
| Forward P/E | 9.76 | — |
| EPS (TTM) | $3.24 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.09B | $125.58M |
| Revenue growth (YoY) | -4.31% | +13.65% |
| Net income (latest FY) | $190.30M | $-91.92M |
| Gross margin | 54.71% | — |
| Operating margin | 28.42% | -141.35% |
| Net margin | 17.48% | -73.20% |
| 52-week high | $71.07 | $40.60 |
| 52-week low | $41.77 | $10.38 |
| Distance from 52-week high | -30.17% | -18.08% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +33.39% | +27.78% |
| Average volume | 583.25K | 1.54M |
| Shares outstanding | 47.40M | 75.04M |
| Employees | 890 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed PBH by 126.1 percentage points over the past year.
- Prestige Consumer Healthcare is more profitable, keeping 17.5 cents of every revenue dollar as net income versus -73.2 cents for Xencor.
- Xencor grew revenue faster in its latest fiscal year (+13.65% vs -4.31%).
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
PBH vs XNCR FAQ
Which is bigger, Prestige Consumer Healthcare or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $2.50B compared with $2.35B for Prestige Consumer Healthcare (PBH).
Which stock has performed better over the past year, PBH or XNCR?
XNCR returned +109.58% over the past 12 months, compared with -16.48% for PBH (price return, excluding dividends). Past performance does not predict future results.
Are Prestige Consumer Healthcare and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.